Eli Lilly's Tirzepatide and China Bio-Collaboration to Drive $2 Trillion Global Pharmaceutical Market by 2032
$2 Trillion Market Driven by Obesity and Inflammation Treatments
According to Evaluate, a global data analysis firm, the global pharmaceutical market is projected to exceed $2 trillion in 2032, driven by treatments for obesity and inflammatory diseases. This mega-trend is increasing market concentration, with the top 20 drugs expected to account for approximately one-fifth of the total market in 2032. In particular, the top five products are expected to become mega-blockbusters, each generating over $20 billion in annual sales. This reflects unmet needs for innovative drugs and indicates that market capital is flowing into specific, high-efficiency pipelines.
Eli Lilly's GLP-1 Dominance and Competitive Landscape
In the diabetes and obesity markets, Eli Lilly's tirzepatide is expected to generate over $70 billion in sales as a single product in 2032, ranking it first. Lilly is strengthening its competitiveness by adding Foundayo (orforglipron), an oral treatment, in addition to tirzepatide, a dual agonist. In contrast, Novo Nordisk's semaglutide franchise is expected to be excluded from the top 10 products due to its relatively weaker weight loss effect compared to competitors. However, Novo Nordisk is also aiming for over $25 billion in annual sales with CagriSema, a combination of amylin agonists.
Leaders in Autoimmune and Anti-Cancer Fields
In addition to metabolic diseases, the immunomodulator field is also expected to continue to grow, surpassing the metabolic field by 2032. AbbVie's Skyrizi, an IL-23 antagonist, is expected to rank second in sales with over $33 billion annually, following tirzepatide. In the anti-cancer field, Daiichi Sankyo and AstraZeneca's Enhertu is ranked 7th, demonstrating the technology of antibody-drug conjugates. Johnson & Johnson's Darzalex and argenx's Vyvgart are also expected to solidify their respective markets.
Rise of Chinese Biotech R&D Pipelines
The strengthening global presence of the Chinese biopharmaceutical industry is one of the most notable aspects of this forecast. Chinese assets are expected to account for more than two-thirds of global deals in 2026. Summit Therapeutics and Chinese Akeso's PD-1/VEGF bispecific antibody, ivonescimab, has the highest net present value in the pipeline, exceeding $25 billion. HanAll Biopharma and Immunovant's co-developed FcRn inhibitor, imeroprubart, is also highly valued.
Challenges in Addressing Patent Cliffs and Geopolitical Risks
The reason why big pharma companies are eager to introduce Chinese pipelines is that by 2032, $500 billion in original drug sales will face generic competition due to patent cliffs. As a result, strategic alliances between U.S. and Chinese biotechs are actively underway, but geopolitical trade conflicts and regulatory changes by the U.S. FDA remain significant risk factors. In the future, global pharmaceutical companies will need to demonstrate their ability to diversify assets and flexibly respond to pricing pressures.
The global pharmaceutical market growth until 2032 will largely depend on the $70 billion obesity market expansion driven by Eli Lilly's tirzepatide and the success of introducing Chinese new pipelines. In the short term, the U.S. FDA's approval of Summit's ivonescimab for non-small cell lung cancer EGFR mutation-positive patients will be a litmus test for evaluating the global expansion potential of Chinese assets. In the medium to long term, establishing joint clinical partnerships between big pharma and Asian developers such as HanAll Biopharma will be essential to defend against the cumulative $500 billion patent expiration risk by 2032. The success of amylin combination drugs or molecular adhesive-based R&D, which are expected to reach Phase 3 completion in the future, will be a decisive factor in determining the ranking of the next generation of blockbuster drugs and re-evaluating corporate value.